Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Crispr Therapeutics Ag (NQ: CRSP)
35.30 USD  +0.24 (+0.68%)
Official Closing Price  /  Updated: 7:07 PM EST, Dec 10, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 909,698
Open 35.06
Bid (Size) 34.58 (1)
Ask (Size) 35.50 (1)
Prev. Close 35.06
Today's Range 34.12 - 36.14
52wk Range 17.40 - 73.90
Shares Outstanding 46,842,969
Dividend Yield N/A
Performance
YTD
+40.25%
+40.25%
1 Month
-2.41%
-2.41%
3 Month
-28.96%
-28.96%
6 Month
-40.74%
-40.74%
1 Year
+91.74%
+91.74%
Top News
More News
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief... Read More
from GlobeNewswire News Releases
New Research Coverage Highlights CAS Medical, Saia, Core Laboratories N.V, Perceptron, CRISPR Therapeutics AG, and IEC Electronics — Consolidated Revenues, Company Growth, and Expectations for 2018
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CAS Medical Systems,... Read More
from GlobeNewswire News Releases
More News
Read More
CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology
from GlobeNewswire News Releases
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2018 Financial Results
from GlobeNewswire News Releases
Here's Why Crispr Therapeutics Rose 17% in November
category Market News , CRSP
from Motley Fool
January 2019 Options Now Available For CRISPR Therapeutics (CRSP)
category Stocks
from Market News Video
Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals
category REGN , VRTX , SNY , and 2 more.
from Motley Fool
Implied JKK Analyst Target Price: $231
category ETFs
from ETF Channel
This Biotech Stock Could Launch Its First CRISPR Drug In 2022
from Investor's Business Daily
Why Crispr Therapeutics Stock Is Up By 65% So Far in 2018
category EDIT , VRTX , NTLA , and 2 more.
from Motley Fool
Why Crispr Therapeutics Stock Is Up 65% So Far in 2018
category NTLA , EDIT , VRTX , and 2 more.
from Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.